Sharemaestro Newsreel

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside

Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.

Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc (IMCR) reported a significant improvement in its financial performance, achieving a first-half 2026 net income of US$12.16 million, up from a net loss of US$5.28 million the previous year, with revenues also increasing. This shift to profitability strengthens the investment case, …

CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages

CorMedix Inc (NASDAQ:CRMD) has received an average "Moderate Buy" rating from brokerages, with six out of eight analysts recommending a buy and two recommending a hold. The company's average 12-month price target is $14.86. This follows a strong second quarter where CorMedix beat revenue …

Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE)

Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another …

TG Therapeutics (TGTX) Raised Revenue Guidance After Q2, Is It Still Below Fair Value?

TG Therapeutics (TGTX) recently reported its Q2 2026 results, showing higher revenue, lower net income, and raised full-year revenue guidance to about US$950 million. Despite a recent 13% drop, the stock is up 64% year-to-date and is considered modestly undervalued at $47.94 against a …

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Summit Therapeutics (SMMT) Expands Ivonescimab Reach As Investors Ask If The Story Is Priced In

Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P

ATAI Beckley earnings beat by $0.03, revenue topped estimates

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Despite a recent 44.2% surge in Moderna's stock price, StockStory advises against investing in the company due to declining revenue and EPS over the last five years, and a negative free cash flow margin. The analysis suggests Moderna is a low-quality business, with the …

Renaissance Technologies (CORT) discloses 4.90% beneficial stake in Corcept Therapeutics

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.90% in Corcept Therapeutics Inc., amounting to 5,261,628 shares of common stock. This Schedule 13G/A filing indicates that Renaissance Technologies holds sole voting and dispositive power over these shares. Certain …

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Investor Relations - Stefanie Perna-NacarPresident and Chief Executive Officer - Jennifer BuellHead of Development - Terese HammondPrincipal Financial Officer - Melissa Orilall TAKEAWAYS Cash and Cash Equivalents -- …

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

Why Absci (ABSI) Is Up 14.0% After Positive Early ABS-201 Hair Loss Data And Endometriosis Plans

Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This …

Capricor Therapeutics Faces Securities Lawsuit

Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans …

Nektar Therapeutics Q2 Earnings Call Highlights

MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johnson) * "At the same time, we continued …

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) reported a quarterly EPS loss of $0.62, missing analyst estimates by $0.02. The company advanced its agenT-797 treatment into a randomized Phase II ARDS trial, with preliminary data expected in the first half of 2027, and launched a paid named-patient access …

(XNCR) as a Liquidity Pulse for Institutional Tactics

This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity

Earnings Call Insights: Cibus, Inc. (CBUS) Q2 2026 MANAGEMENT VIEW * CEO Craig Wichner framed his priorities around scaling revenue and tighter spending control, saying, "I accepted the job of CEO because I believe we can generate revenue at scale. That is my mission." …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

Top Kailera Therapeutics (KLRA) Competitors 2026